Abstract
Acetylcysteine has been used to treat acetaminophen overdose for nearly 50 years. While no placebo controlled trials have been conducted, the efficacy of acetylcysteine is accepted for the prevention of hepatic injury when administered early after acetaminophen overdose. Acetylcysteine can be administered as an infusion or oral solution. The duration of treatment varies from 21 to 72 hours, depending on the protocol. Acetylcysteine also prevents death when administered to patients with hepatic failure from acetaminophen.
Keywords: Acetaminophen, acetylcysteine, hepatic failure, overdose, placebo, Acetaminophen poisoning, CYP2E1, Nacetyl-p-benzoquinoneimine (NAPQI), minor metabolic pathway, therapeutic dose, hepatic injury, antidotes, glutathione, hepatic injury.
Current Pharmaceutical Biotechnology
Title:Acetylcysteine Therapy for Acetaminophen Poisoning
Volume: 13 Issue: 10
Author(s): Kennon Heard and Jody Green
Affiliation:
Keywords: Acetaminophen, acetylcysteine, hepatic failure, overdose, placebo, Acetaminophen poisoning, CYP2E1, Nacetyl-p-benzoquinoneimine (NAPQI), minor metabolic pathway, therapeutic dose, hepatic injury, antidotes, glutathione, hepatic injury.
Abstract: Acetylcysteine has been used to treat acetaminophen overdose for nearly 50 years. While no placebo controlled trials have been conducted, the efficacy of acetylcysteine is accepted for the prevention of hepatic injury when administered early after acetaminophen overdose. Acetylcysteine can be administered as an infusion or oral solution. The duration of treatment varies from 21 to 72 hours, depending on the protocol. Acetylcysteine also prevents death when administered to patients with hepatic failure from acetaminophen.
Export Options
About this article
Cite this article as:
Heard Kennon and Green Jody, Acetylcysteine Therapy for Acetaminophen Poisoning, Current Pharmaceutical Biotechnology 2012; 13 (10) . https://dx.doi.org/10.2174/138920112802273146
DOI https://dx.doi.org/10.2174/138920112802273146 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results
Current Cardiology Reviews Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Reversal of Resistance to Oxazaphosphorines
Current Cancer Drug Targets Characterization and Antihypertensive Effect of the Complex of (-)-β- pinene in β-cyclodextrin
Current Pharmaceutical Biotechnology Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia
Current Medicinal Chemistry The Key Role of Medullary 5-HT3 Receptors in the Serotonin-Mediated Neural Control of Cardiovascular Function
Current Neuropharmacology Inflammatory Caspases: Targets for Novel Therapies
Current Pharmaceutical Design New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Editorial [ Hot Topic:Addiction and Pain: Cannabinoid and Opioid Interactions (Guest Editor: Sonia Tucci) ]
Current Drug Targets Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1
Current Drug Targets Meta-Analysis of Creatine for Neuroprotection Against Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Targeting of TRPV1 by Resiniferatoxin, from Preclinical Studies to Clinical Trials
Current Topics in Medicinal Chemistry Artemia species: An Important Tool to Screen General Toxicity Samples
Current Pharmaceutical Design New Therapies for Sepsis
Current Topics in Medicinal Chemistry Stroke and Hypertension: An Appraisal from Pathophysiology to Clinical Practice
Current Vascular Pharmacology Intra-arterial Instillation of a Nociceptive Agent Modulates Cardiorespiratory Parameters Involving 5-HT3 and TRPV1 Receptors in Anesthetized Rats
Cardiovascular & Hematological Disorders-Drug Targets